Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 | P04049 | 12/20 | 0.82 |
| ▸ | KDR | P35968 | 6/20 | 0.82 |
| ▸ | BRAF | P15056 | 5/20 | 0.82 |
| ▸ | RET | P07949 | 3/20 | 0.82 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.82 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.82 |
| ▸ | ABL1 | P00519 | 2/20 | 0.82 |
| ▸ | HTR1A | P08908 | 2/20 | 0.82 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.82 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.82 |
| ▸ | KIT | P10721 | 2/20 | 0.82 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.82 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.82 |
| ▸ | FLT1 | P17948 | 2/20 | 0.82 |
| ▸ | MAOA | P21397 | 2/20 | 0.82 |
| ▸ | EPHA1 | P21709 | 2/20 | 0.82 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.82 |
| ▸ | EPHA2 | P29317 | 2/20 | 0.82 |
| ▸ | TTK | P33981 | 2/20 | 0.82 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.82 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sorafenib SCHEMBL29349634 | 0.90 | RAF1 (1.00) | RAF1KDRBRAFRETRIPK2 | |
| Sorafenib SCHEMBL14739751 | 0.90 | RAF1 (1.00) | RAF1KDRBRAFRETRIPK2 | |
| Sorafenib SCHEMBL8218 | 0.90 | RAF1 (1.00) | RAF1KDRBRAFRETRIPK2 | |
| Sorafenib SCHEMBL28817561 | 0.90 | RAF1 (0.98) | RAF1KDRBRAFRETRIPK2 | |
| Sorafenib SCHEMBL1533976 | 0.90 | RAF1 (0.98) | RAF1KDRBRAFRETRIPK2 | |
| Sorafenib SCHEMBL28894639 | 0.90 | RAF1 (0.98) | RAF1KDRBRAFRETRIPK2 | |
| Sorafenib SCHEMBL1896610 | 0.90 | RAF1 (0.98) | RAF1KDRBRAFRETRIPK2 | |
| Sorafenib SCHEMBL1533982 | 0.90 | RAF1 (0.98) | RAF1KDRBRAFRETRIPK2 | |
| Sorafenib SCHEMBL18863920 | 0.90 | RAF1 (0.98) | RAF1KDRBRAFRETRIPK2 | |
| Sorafenib SCHEMBL1533981 | 0.90 | RAF1 (0.98) | RAF1KDRBRAFRETRIPK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230233691-A1 | METHODS AND COMPOSITIONS FOR TREATING CHRONIC INFLAMMATORY INJURY, METAPLASIA, DYSPLASIA AND CANCERS OF EPITHELIAL TISSUES | UNIVERSITY OF HOUSTON SYSTEM (US) | 2023-07-27 | — | — | US | disclosed |
| US-20220202792-A1 | METHODS AND COMPOSITIONS FOR TREATING CHRONIC INFLAMMATORY INJURY, METAPLASIA, DYSPLASIA AND CANCERS OF EPITHELIAL TISSUES | UNIVERSITY OF HOUSTON SYSTEM (US) | 2022-06-30 | — | — | US | disclosed |
| US-20210401987-A1 | METHODS AND COMPOSITIONS FOR TREATING INFLAMMATORY AND FIBROTIC PULMONARY DISORDERS | UNIVERSITY OF HOUSTON SYSTEM (US) | 2021-12-30 | — | — | US | disclosed |
| US-20150267258-A1 | BIOMARKERS FOR DETERMINING EFFECTIVE RESPONSE OF TREATMENTS OF HEPATOCELLULAR CARCINOMA (HCC) PATIENTS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210401987-A1 | METHODS AND COMPOSITIONS FOR TREATING INFLAMMATORY AND FIBROTIC PULMONARY DISORDERS | MMP1, MMP8, CCL11 | RAF1 2232/4885KDR 3463/4885BRAF 3645/4885 |
| US-20230233691-A1 | METHODS AND COMPOSITIONS FOR TREATING CHRONIC INFLAMMATORY INJURY, METAPLASIA, DYSPLASIA AND CANCERS OF EPITHELIAL TISSUES | FABP2, MYADM, FABP6 | RAF1 1205/4885KDR 2501/4885BRAF 644/4885 |
| US-20220202792-A1 | METHODS AND COMPOSITIONS FOR TREATING CHRONIC INFLAMMATORY INJURY, METAPLASIA, DYSPLASIA AND CANCERS OF EPITHELIAL TISSUES | FABP2, MUC1, FABP6 | RAF1 932/4885KDR 3559/4885BRAF 703/4885 |
| US-20150267258-A1 | BIOMARKERS FOR DETERMINING EFFECTIVE RESPONSE OF TREATMENTS OF HEPATOCELLULAR CARCINOMA (HCC) PATIENTS | NRAS, KRAS, TP53 | RAF1 9/4885KDR 120/4885BRAF 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.